Can I Take St. John's Wort With AndroGel?

Why This Combination Deserves a Direct Answer

Men prescribed AndroGel for hypogonadism frequently explore over-the-counter supplements for depression, anxiety, or seasonal mood changes. St. John's Wort (Hypericum perforatum) is one of the most purchased herbal products in the United States, with annual retail sales exceeding $30 million. The problem is that St. John's Wort has a well-documented ability to reduce plasma concentrations of dozens of prescription drugs, and testosterone is metabolized through some of those same pathways.

The Scope of the Problem

The FDA issued a public health advisory on St. John's Wort interactions as early as February 2000, warning that the herb induces cytochrome P450 enzymes and the drug transporter P-glycoprotein, leading to clinically meaningful reductions in drug exposure for co-administered medications [1]. Since that advisory, over 50 distinct drug classes have been identified as susceptible to this interaction, including antiretrovirals, oral contraceptives, cyclosporine, and warfarin [2].

Testosterone is not always the first drug people think of in this context. Most interaction databases focus on drugs with narrow therapeutic windows. Yet for a man whose hypogonadism is already difficult to manage, even a 20 to 30 percent drop in circulating testosterone could push levels back below the symptomatic threshold of roughly 300 ng/dL.

Who Is Most at Risk

Men at highest risk are those taking lower-end AndroGel doses (20.25 mg to 40.5 mg per day of the 1.62% formulation) whose trough testosterone levels are already near the bottom of the therapeutic range. Men with impaired transdermal absorption due to skin conditions, high body-fat percentage, or application-site variability are also more vulnerable. Starting St. John's Wort in this population may be enough to tip pre-existing borderline levels into frank deficiency.

How St. John's Wort Affects Drug Metabolism

St. John's Wort contains two primary active constituents: hypericin and hyperforin. Hyperforin is the compound responsible for enzyme induction. It activates the pregnane X receptor (PXR), a nuclear receptor that controls transcription of CYP3A4, CYP2C9, and the drug efflux transporter MDR1 (P-glycoprotein) [2].

CYP3A4 and Testosterone Clearance

Testosterone undergoes hepatic hydroxylation primarily via CYP3A4, producing 6-beta-hydroxytestosterone as the main metabolite [3]. When CYP3A4 activity is upregulated by hyperforin, the rate of testosterone hydroxylation increases. The result is faster clearance and lower steady-state plasma concentrations. A study published in Clinical Pharmacology and Therapeutics demonstrated that St. John's Wort extract (300 mg three times daily standardized to 0.3% hypericin) reduced the AUC of the CYP3A4 probe drug midazolam by approximately 50 to 75 percent after 14 days of co-administration [4]. While no identically designed study has been performed specifically with transdermal testosterone, the metabolic pathway overlap makes a comparable reduction biologically plausible.

P-Glycoprotein and Intestinal Absorption

P-glycoprotein is an efflux pump expressed in gut epithelium, the blood-brain barrier, and hepatocytes. For AndroGel applied transdermally, P-gp upregulation is less directly relevant to absorption than it would be for an orally administered drug. However, P-gp induction in hepatocytes may contribute to first-pass-equivalent hepatic clearance of testosterone that reaches systemic circulation [5]. The net effect compounds the CYP3A4-driven clearance increase.

Time Course of Induction

Enzyme induction is not instantaneous. Measurable CYP3A4 induction from St. John's Wort appears within 3 to 7 days of daily dosing and reaches a plateau at approximately 14 days [4]. When St. John's Wort is discontinued, enzyme activity returns to baseline within 1 to 2 weeks as normal protein turnover replaces the upregulated enzymes. This timeline matters clinically: a man who stops St. John's Wort and checks his testosterone the very next day will likely still see suppressed levels.

What the Clinical Evidence Says About Testosterone Specifically

No large randomized controlled trial has directly studied St. John's Wort plus AndroGel in hypogonadal men. The evidence for this interaction is built from three lines of data: pharmacokinetic studies of CYP3A4 induction, the known CYP3A4-dependence of testosterone metabolism, and case reports of reduced efficacy for other hormone therapies.

CYP3A4 Probe Studies

The most cited quantitative data come from studies using oral midazolam or cyclosporine as CYP3A4 probes. A 2003 trial by Hebert et al. Found that St. John's Wort 300 mg three times daily for 14 days reduced cyclosporine blood levels by 46 to 52 percent in stable renal transplant patients, leading to acute rejection episodes in two of the ten subjects [6]. Cyclosporine, like testosterone, is a CYP3A4 substrate with a narrow effective range. The magnitude of the interaction in that study is consistent with the degree of CYP3A4 induction documented in enzymatic assays.

Oral Contraceptive Analogy

Oral contraceptives contain ethinyl estradiol and progestins, both CYP3A4 substrates. Multiple pharmacokinetic studies and the FDA-approved labeling for several contraceptives now explicitly warn that St. John's Wort reduces contraceptive hormone exposure by 13 to 15 percent and substantially increases breakthrough bleeding and unintended pregnancy risk [1]. The analogy to testosterone is not perfect because route of administration differs, but the shared metabolic pathway supports concern. Sex steroids as a class appear susceptible to this induction mechanism.

Testosterone-Specific Case Evidence

The Natural Medicines comprehensive database (formerly Natural Standard) classifies the St. John's Wort-testosterone interaction as "moderate" based on mechanistic plausibility and extrapolated pharmacokinetic data [7]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism does not specifically name St. John's Wort, but instructs clinicians to "review all concomitant medications and herbal supplements that affect CYP3A4 before initiating or adjusting testosterone therapy" [8]. That instruction covers St. John's Wort by definition.

The framework below summarizes how to categorize the risk in clinical practice. Men with trough testosterone levels below 450 ng/dL at steady-state AndroGel dosing should be considered high-risk for any CYP3A4 interaction. Men above 600 ng/dL at current dosing have a larger buffer and may experience a reduction that still keeps them within range, though monitoring is still mandatory.

CYP3A4 Interaction Risk Stratification for AndroGel Users

| Trough Testosterone at Current Dose | St. John's Wort Risk Category | Suggested Action | |---|---|---| | <300 ng/dL | Very High | Do not start; optimize dose first | | 300 to 449 ng/dL | High | Avoid; choose alternative mood support | | 450 to 599 ng/dL | Moderate | Avoid; if unavoidable, recheck T in 2 weeks | | 600 to 700 ng/dL | Lower (but not absent) | Discuss with prescriber; monitor monthly | | >700 ng/dL | Lowest (still present) | Discuss with prescriber; monitor quarterly |

AndroGel Pharmacokinetics: Why Transdermal Route Does Not Eliminate the Risk

A common misconception is that transdermal testosterone bypasses hepatic metabolism entirely and therefore avoids CYP3A4-based interactions. This is incorrect.

First-Pass Is Avoided, But Hepatic Clearance Is Not

Transdermal delivery does avoid intestinal first-pass metabolism, which is one reason AndroGel produces more stable serum levels than oral testosterone undecanoate. However, testosterone absorbed through skin still enters systemic circulation and passes through the liver repeatedly during its elimination phase. Hepatic CYP3A4 handles a meaningful fraction of systemic testosterone clearance with each hepatic pass [3]. Inducing CYP3A4 in the liver therefore increases total body clearance of transdermally delivered testosterone, reducing the steady-state AUC.

Protein Binding and Free Testosterone

Approximately 44 percent of circulating testosterone is bound to sex hormone-binding globulin (SHBG), 54 percent is loosely bound to albumin, and roughly 2 to 3 percent circulates free [9]. St. John's Wort does not directly alter SHBG. The interaction operates solely through increased metabolic clearance of total testosterone. Because free testosterone tracks proportionally with total testosterone in most physiological states, a drop in total testosterone will reduce free testosterone by a comparable percentage, worsening symptomatic deficiency.

Steady-State Kinetics With AndroGel

AndroGel 1.62% achieves steady-state in approximately 7 days of daily application [10]. If a patient initiates St. John's Wort after reaching steady state, the new, lower steady-state will be established over the following 7 to 14 days as CYP3A4 induction matures. This means a man might feel fine for the first week and only notice worsening fatigue, low libido, or mood decline at week 2 to 3, which could obscure the connection to the herbal supplement if the timeline is not tracked carefully.

Symptoms That Should Prompt a Testosterone Check

Men using both AndroGel and St. John's Wort who notice any of the following symptoms within 2 to 4 weeks of starting the herb should contact their prescriber and request a morning serum testosterone level:

• Fatigue that was previously managed returning
• Reduced libido or erectile dysfunction reappearing
• Mood changes, including increased irritability or flat affect
• Reduced motivation or cognitive slowing
• Unexpected changes in muscle strength or body composition

These symptoms overlap with the indication for St. John's Wort (depression, low mood), which creates a diagnostic trap. A man taking the herb for depression may attribute worsening mood to the underlying condition when the cause is actually falling testosterone levels from the interaction.

What to Do If You Are Already Taking Both

Step 1: Do Not Stop Either Abruptly Without Medical Guidance

Abrupt testosterone discontinuation can cause a transient hypogonadal state with rebound symptoms. Stopping St. John's Wort mid-course can cause serotonin-related discontinuation symptoms in some users, though the herb's serotonin mechanism is weaker than that of prescription SSRIs.

Step 2: Get a Baseline Testosterone Level Immediately

Request a morning (7:00 to 10:00 AM) serum total and free testosterone. The Endocrine Society recommends measuring testosterone 2 to 4 hours after AndroGel application for 1% gel and following the product-specific pharmacokinetic window for 1.62% gel [8]. If the level is below 400 ng/dL, the interaction may already be clinically active.

Step 3: Discuss Discontinuing St. John's Wort With Your Prescriber

Most prescribers will recommend stopping St. John's Wort and transitioning to an evidence-based alternative for mood support. Options include sertraline 50 to 200 mg/day (FDA-approved for major depressive disorder and social anxiety disorder), escitalopram 10 to 20 mg/day, or structured psychotherapy. A 2016 Cochrane review of St. John's Wort for depression (N = 5,489 patients across 27 trials) found it "superior to placebo in patients with major depression" but noted that "available evidence is insufficient to adequately compare the herb with established antidepressants" [11]. Given that prescription antidepressants do not share the CYP3A4 induction mechanism, they are a safer choice for men on testosterone therapy.

Step 4: Recheck Testosterone Two Weeks After Stopping St. John's Wort

Allow 14 days for CYP3A4 activity to normalize, then repeat morning testosterone. If levels remain below target, the prescriber may need to uptitrate the AndroGel dose. Endocrine Society guidelines allow dose escalation from 40.5 mg to 81 mg per day for the 1.62% formulation if trough levels are inadequate [8].

Monitoring Protocol for AndroGel Users Starting Any CYP3A4-Active Supplement

The principles below apply beyond St. John's Wort to other CYP3A4 inducers sometimes used as supplements, including ashwagandha (weak inducer, evidence mixed), black cohosh (weak CYP3A4 effects), and high-dose vitamin D (minimal clinical induction in most studies but worth tracking).

Strong CYP3A4 inducers beyond St. John's Wort that men on AndroGel should discuss with their prescriber before use:

• Rifampin (antibiotic, strongest known inducer)
• Carbamazepine (anticonvulsant)
• Phenytoin (anticonvulsant)
• Phenobarbital (sedative/anticonvulsant)
• Efavirenz, nevirapine (antiretrovirals)

The FDA's drug interaction database at accessdata.fda.gov provides an updated list of known CYP3A4 inducers and inhibitors relevant to testosterone products [10].

The Prescriber's Perspective on Herbal Supplement Disclosure

Research consistently shows that patients underreport herbal supplement use to their physicians. A 2017 survey published in JAMA Internal Medicine found that 69 percent of adults using complementary medicines did not disclose this to their primary care provider, most commonly because "the doctor didn't ask" [12]. For men on AndroGel, this is a patient safety concern.

The Endocrine Society's 2018 guideline explicitly states: "Clinicians should ask about the use of medications and substances that interfere with testosterone action or metabolism, including herbs and supplements, at every follow-up visit." [8]

Bringing a complete supplement list (including brand, dose, and frequency) to every AndroGel follow-up visit gives the prescriber the information needed to interpret testosterone lab results accurately.

Key Takeaway for Patients

Avoid St. John's Wort if you are using AndroGel unless your prescriber has reviewed your testosterone levels, confirmed you have adequate buffer above the therapeutic threshold, and established a monitoring plan. The interaction is pharmacokinetically real, clinically plausible based on CYP3A4 probe data, and preventable with straightforward communication. Men seeking mood support have safer pharmacological options that do not interfere with testosterone metabolism.

The Endocrine Society 2018 clinical practice guideline sets a target trough testosterone of 400 to 700 ng/dL during AndroGel therapy. If St. John's Wort reduces your level by even 20 percent from a starting trough of 450 ng/dL, you will land at 360 ng/dL, a range still technically within the normal male reference interval but below the guideline treatment target and likely symptomatic for many men [8].